Created at Source Raw Value Validated value
Nov. 12, 2021, 5:03 p.m. oms

Subjects who comply with the following criteria will be enrolled: 1. Willing to participate in the study with informed consent, 2. Health male or female adults (i.e. aged 18 years and above), 3. BMI within 18-28 kg/m2 (including both boundaries), 4. Without a history of traveling or residence in domestic areas of high and moderate pandemic risk, overseas or epidemic areas, nor a history of contact with confirmed, asymptomatic or suspected COVID-19 cases, or patients coming from areas of high and moderate pandemic risk who have fever or respiratory tract symptoms within the past 14 days, being not in quarantine and not living in an area with cluster of COVID-19 cases, 5. Males with fertility and women of childbearing potential who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 12 months after the last dose of the investigational vaccines, women of childbearing potential refer to premenopausal women and women within 2 years after menopause. Women of childbearing potential should test negative for pregnancy within 7 days prior to the first dose of the investigational vaccines, 6. Willing to abide by the study protocol by cooperatively receiving required examinations.

Subjects who comply with the following criteria will be enrolled: 1. Willing to participate in the study with informed consent, 2. Health male or female adults (i.e. aged 18 years and above), 3. BMI within 18-28 kg/m2 (including both boundaries), 4. Without a history of traveling or residence in domestic areas of high and moderate pandemic risk, overseas or epidemic areas, nor a history of contact with confirmed, asymptomatic or suspected COVID-19 cases, or patients coming from areas of high and moderate pandemic risk who have fever or respiratory tract symptoms within the past 14 days, being not in quarantine and not living in an area with cluster of COVID-19 cases, 5. Males with fertility and women of childbearing potential who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 12 months after the last dose of the investigational vaccines, women of childbearing potential refer to premenopausal women and women within 2 years after menopause. Women of childbearing potential should test negative for pregnancy within 7 days prior to the first dose of the investigational vaccines, 6. Willing to abide by the study protocol by cooperatively receiving required examinations.

April 14, 2021, 2:05 p.m. oms

Subjects who comply with the following criteria will be enrolled: 1) Willing to participate in the study with informed consent, 2) Health male or female adults (i.e. aged 18 years and above), 3) BMI within 18-28 kg/m2 (including both boundaries), 4) Without a history of traveling or residence in domestic areas of high and moderate pandemic risk, overseas or epidemic areas, nor a history of contact with confirmed, asymptomatic or suspected COVID-19 cases, or patients coming from areas of high and moderate pandemic risk who have fever or respiratory tract symptoms within the past 14 days, being not in quarantine and not living in an area with cluster of COVID-19 cases, 5) Males with fertility and women of childbearing potential who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 12 months after the last dose of the investigational vaccines, women of childbearing potential refer to premenopausal women and women within 2 years after menopause. Women of childbearing potential should test negative for pregnancy within 7 days prior to the first dose of the investigational vaccines, 6) Willing to abide by the study protocol by cooperatively receiving required examinations.

Subjects who comply with the following criteria will be enrolled: 1) Willing to participate in the study with informed consent, 2) Health male or female adults (i.e. aged 18 years and above), 3) BMI within 18-28 kg/m2 (including both boundaries), 4) Without a history of traveling or residence in domestic areas of high and moderate pandemic risk, overseas or epidemic areas, nor a history of contact with confirmed, asymptomatic or suspected COVID-19 cases, or patients coming from areas of high and moderate pandemic risk who have fever or respiratory tract symptoms within the past 14 days, being not in quarantine and not living in an area with cluster of COVID-19 cases, 5) Males with fertility and women of childbearing potential who are willing to take effective contraceptive measures during the period from the date of signing the informed consent to 12 months after the last dose of the investigational vaccines, women of childbearing potential refer to premenopausal women and women within 2 years after menopause. Women of childbearing potential should test negative for pregnancy within 7 days prior to the first dose of the investigational vaccines, 6) Willing to abide by the study protocol by cooperatively receiving required examinations.